GARS Antikörper (AA 43-289)
Kurzübersicht für GARS Antikörper (AA 43-289) (ABIN5540351)
Target
Alle GARS Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 43-289
-
Aufreinigung
- Protein-A affinity chromatography
-
Immunogen
- Recombinant human GARS (43-289aa) purified from E. coli.
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- The antibody has been tested by ELISA, Western blot analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results. Recommended starting dilution is 1:500
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- PBS, pH 7.4 containing 0.02 % Sodium Azide and 10 % Glycerol
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store undiluted at 2-8°C for up to two weeks or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Shelf life: one year from despatch.
-
Haltbarkeit
- 12 months
-
-
- GARS (Glycyl-tRNA Synthetase (GARS))
-
Andere Bezeichnung
- glycyl-trna synthetase
-
Hintergrund
- GARS, also known as glycyl-tRNA synthetase, is one of the aminoacyl-tRNA synthetase that charge tRNAs with their cognate amino acids. Defects in the gene encoding GlyRS is the cause of Charcot-Marie-Tooth disease type 2D (CMT2D), which is an autosomal dominant inherited disease characterized by severe weakness, atrophy and absence of deep tendon reflexes in the upper extremities. Defects in the GlyRS gene is also the cause of distal hereditary muscular neuropathy type V (HMN5), a disease similar to CMT2D, though the distal sensory involvement is less severe in HMN5 patients.
-
UniProt
- P41250
-
Pathways
- Ribonucleoside Biosynthetic Process
Target
-